HSBC has downgraded Biogen Inc (BIIB) to a rating of Reduce from Hold as of December 9, 2025. The current share price stands at $179.14. This decision underscores a growing caution regarding Biogen's outlook, potentially reflecting competitive pressures, market conditions, or execution risks that could affect the company's performance.
Biogen, headquartered in Cambridge, Massachusetts, operates within the biotechnology sector, focusing on therapies for neurological and neurodegenerative diseases. The company employs 7,605 full-time staff and boasts a market capitalization of $26.8 billion, with a trailing P/E ratio of 16.68 and an EPS of 10.97.
Upcoming earnings reports are scheduled for April 29, 2026, with an estimated EPS of $3.55 and revenue of $2.3 billion, followed by another report on July 29, 2026, where EPS is projected at $3.91 and revenue at $2.4 billion.
Analyst ratings and price targets provide insights based on research and financial models, reflecting assumptions that may not always materialize. Investment decisions should incorporate a variety of factors, including company fundamentals, competitive positioning, and industry trends. Analyst views should be considered among many inputs when making investment choices.
As of December 1, 2025, the analyst consensus for Biogen remains a Buy, with 9 Strong Buy, 12 Buy, 21 Hold, and no Sell or Strong Sell ratings.